Overweight breast cancer survivors treated with tamoxifen may have higher risk for arm lymphedema
the ONA take:
Breast cancer survivors with a body mass index (BMI) >25 who report the use of tamoxifen therapy may be at increased risk for arm lymphedema, according to a recent study published in the Journal of Cancer Survivorship.
For the study, researchers analyzed data from 43 women breast cancer who reported physician-diagnosed lymphedema during follow-up of the long-term quality of life (LTQOL) study in order to investigate whether an association exists between treatment-related risk factors and development of arm lymphedema.
Results showed that tamoxifen had a non-significant, positive association with arm lymphedema, but type of surgery, radiation, or chemotherapy had no impact on the risk of lymphedema development. Researchers found that the risk for developing arm lymphedema was particularly higher among overweight and obese women with a BMI greater than 25 who were treated with tamoxifen.
"Lymphedema risk may be another indication to consider a weight reduction program in breast cancer survivors," the authors conclude.
Breast cancer survivors with a body mass index (BMI) >25 who report the use of tamoxifen therapy may be at increased risk for arm lymphedema.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|